Harmony Biosciences Holdings (HRMY) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Harmony Biosciences Holdings (HRMYResearch Report) today and set a price target of $64.00. The company’s shares closed last Monday at $49.23.

According to TipRanks.com, Suvannavejh is a 2-star analyst with an average return of 0.7% and a 49.0% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Intra-Cellular Therapies, and Bioxcel Therapeutics.

Harmony Biosciences Holdings has an analyst consensus of Strong Buy, with a price target consensus of $60.25, representing a 22.4% upside. In a report issued on July 18, Needham also maintained a Buy rating on the stock with a $60.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $57.13 and a one-year low of $25.94. Currently, Harmony Biosciences Holdings has an average volume of 520.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.

Read More on HRMY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More